Table 1.
Baseline* Characteristics
| Characteristic | Receipt of TCAs† (N = 5,190) | Receipt of SSRIs† (N = 54,948) | No Antidepressant Use† (N = 68,063) | P value |
|---|---|---|---|---|
|
| ||||
| Age in years, median (IQR) | 52.0 (48.0, 57.0) | 52.0 (47.3, 56.0) | 55.0 (50.0, 60.0) | <0.01 |
|
| ||||
| Race, % | ||||
|
| ||||
| White | 54.9 | 57.4 | 52.5 | <0.01 |
|
| ||||
| Black | 32.3 | 28.6 | 31.7 | |
|
| ||||
| Hispanic | 3.6 | 4.4 | 3.3 | |
|
| ||||
| Other | 9.2 | 9.6 | 12.4 | |
|
| ||||
| Sex, % male | 97.0 | 96.0 | 97.5 | <0.01 |
|
| ||||
| Baseline median HCV RNA (IQR), log10 | 4.7 (1.6, 6.5) 1683 missing |
5.0 (1.6, 6.5) 17624 missing |
5.0 (1.6, 6.6) 19038 missing |
0.70 |
|
| ||||
| HCV genotype, % | ||||
|
| ||||
| 1 | 27.7 | 31.0 | 29.0 | |
|
| ||||
| 2 | 3.1 | 3.9 | 3.6 | |
|
| ||||
| 3 | 2.2 | 2.4 | 1.9 | |
|
| ||||
| 4 | 0.3 | 0.3 | 0.2 | <0.01 |
|
| ||||
| Mix | 0.2 | 0.2 | 0.1 | |
|
| ||||
| Missing | 66.6 | 62.3 | 65.1 | |
|
| ||||
| BMI, median (IQR) | 27.2 (23.9, 30.9) | 27.0 (23.9, 30.7) | 26.9 (23.7, 30.5) | <0.01 |
|
| ||||
| Diabetes, % | 25.1 | 15.6 | 17.0 | <0.01 |
|
| ||||
| Hypertension, % | 51.7 | 44.5 | 47.4 | <0.01 |
|
| ||||
| Alcohol abuse or dependence, % | 32.1 | 41.9 | 25.6 | <0.01 |
|
| ||||
| Drug abuse or dependence, % | 34.0 | 42.6 | 25.9 | <0.01 |
|
| ||||
| Baseline APRI score, median (IQR) | 0.39 (0.25,0.65) | 0.41(0.26,0.68) | 0.40(0.26,0.67) | <0.01 |
|
| ||||
| Median ALT (IQR), IU/mL | 41 (27, 66) | 43 (27, 70) | 40 (26, 66) | <0.01 |
|
| ||||
| Median AST (IQR), IU/mL | 35 (25, 53) | 36 (26, 55) | 35 (25, 54) | <0.01 |
|
| ||||
| Completed a course of HCV treatment, % | 3.2 | 4.6 | 3.6 | <0.01 |
|
| ||||
| Baseline lipid levels median, (IQR) | ||||
| Triglycerides | 122 (85,184) Missing: 746 |
117(81,174) Missing: 8940 |
109 (76,161) Missing: 9195 |
<0.01 |
| LDL | 101 (78, 126) Missing: 1065 |
103 (81, 127) Missing: 11577 |
101 (79, 152) Missing: 11811 |
<0.01 |
| HDL | 42 (34, 54) Missing: 879 |
43 (35, 54) Missing: 10568 |
43 (35, 54) Missing: 10382 |
<0.01 |
| Total cholesterol | 173 (149, 202) Missing: 628 |
176 (151, 203) Missing: 7315 |
173 (148, 200) Missing: 7841 |
<0.01 |
|
| ||||
| Anemia, % | 13.2 | 9.9 | 13.2 | <0.01 |
|
| ||||
| Follow-up variables, % | ||||
|
| ||||
| Developed incident cirrhosis (APRI > 2) | 20.8 | 24.3 | 17.3 | <0.01 |
|
| ||||
| Developed HCC | 2.9 | 2.6 | 2.5 | 0.12 |
*
Values obtained at baseline or closest value within 12 months of baseline.
†
TCA use was defined as TCA ≥28 cDDD per year and no SSRI use, and SSRI use was defined as ≥28 cDDD per year and no TCA use. Subjects were considered to use no antidepressants if they met any of the following criteria: (1) no receipt of SSRIs or TCAs; (2) SSRI receipt <28 cDDD; and (3) TCA receipt <28 cDDD.
Abbreviations: BMI, body mass index; ALT, alanine aminotransferase; AST, aspartate aminotransferase; PEG, pegylated interferon; LDL, low- density lipoprotein; HDL, high-density lipoprotein; HCC, hepatocellular carcinoma.